Praxis Precision Medicines (NASDAQ:PRAX) continued to climb on Thursday, adding more than 200% in the afternoon session as Wall Street welcomed a late-stage trial success for lixacaltamide, its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback